Please use this identifier to cite or link to this item: https://repositorio.unifesp.br/handle/11600/38718
Full metadata record
DC FieldValueLanguage
dc.contributor.authorLindsey, Susan C. [UNIFESP]
dc.contributor.authorGanly, Ian
dc.contributor.authorPalmer, Frank
dc.contributor.authorTuttle, R. Michael
dc.date.accessioned2016-01-24T14:40:01Z-
dc.date.available2016-01-24T14:40:01Z-
dc.date.issued2015-02-01
dc.identifierhttp://dx.doi.org/10.1089/thy.2014.0277
dc.identifier.citationThyroid. New Rochelle: Mary Ann Liebert, Inc, v. 25, n. 2, p. 242-249, 2015.
dc.identifier.issn1050-7256
dc.identifier.urihttp://repositorio.unifesp.br/handle/11600/38718-
dc.description.abstractBackground: Risk stratification in medullary thyroid cancer (MTC) has traditionally relied on standardized anatomic staging systems that, despite providing valuable prognostic information, do not adequately predict the risk of persistent or recurrent disease. As dynamic risk stratification has been demonstrated to be clinically valuable in nonmedullary thyroid cancer, we adapted our response to therapy definitions in order to apply them to MTC. in this study, we evaluate and compare the clinical utility of our previously proposed MTC response to therapy stratification with a traditional standardized anatomic staging system.Methods: Both the Tumor, Node, Metastasis/American Joint Cancer Committee (TNM/AJCC) staging system and our previously proposed response to initial therapy staging system was evaluated in 287 MTC patients followed for a median of five years.Results: the TNM/AJCC staging system provided adequate risk stratification with regard to disease-specific mortality and the likelihood of having no evidence of disease at final follow-up, but did not adequately stratify patients with regard to the likelihood of having structural persistent disease, biochemical persistent disease, or recurrence. However, the response to initial therapy risk stratification system provided clinically useful risk stratification with regard to disease-specific mortality, the likelihood of having no evidence of disease at final follow-up, the likelihood of having a biochemical persistent disease at final follow-up, and the likelihood of having structural persistent disease at final follow-up. Furthermore, the response to therapy risk stratification system demonstrated a higher proportion of variance explained (54.3%) than the TNM/AJCC system (23.9%).Conclusion: Our data demonstrate that a dynamic risk stratification system that uses response to therapy variables to adjust risk estimates over time provides more useful clinical prognostic information than static initial anatomic staging in MTC thyroid cancer.en
dc.description.sponsorshipFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
dc.format.extent242-249
dc.language.isoeng
dc.publisherMary Ann Liebert, Inc
dc.relation.ispartofThyroid
dc.rightsAcesso restrito
dc.titleResponse to Initial Therapy Predicts Clinical Outcomes in Medullary Thyroid Canceren
dc.typeArtigo
dc.contributor.institutionUniversidade Federal de São Paulo (UNIFESP)
dc.contributor.institutionMem Sloan Kettering Canc Ctr
dc.description.affiliationUniversidade Federal de São Paulo, Escola Paulista Med, Dept Med, Lab Mol & Translat Endocrinol, São Paulo, Brazil
dc.description.affiliationMem Sloan Kettering Canc Ctr, Dept Head & Neck Surg, New York, NY 10021 USA
dc.description.affiliationMem Sloan Kettering Canc Ctr, Serv Endocrinol, New York, NY 10021 USA
dc.description.affiliationUnifespUniversidade Federal de São Paulo, Escola Paulista Med, Dept Med, Lab Mol & Translat Endocrinol, São Paulo, Brazil
dc.description.sponsorshipIDFAPESP: 09/50575-4
dc.identifier.doi10.1089/thy.2014.0277
dc.description.sourceWeb of Science
dc.identifier.wosWOS:000349012300014
Appears in Collections:Em verificação - Geral

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.